FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367305046> ?p ?o ?g. }

• W4367305046 abstract "<h3>Objective:</h3> Characterize the natural history of ALSP by imaging, biomarkers, and standardized clinical measurements to inform the design of future clinical trials testing novel therapeutics for ALSP. <h3>Background:</h3> ALSP is a rare, rapidly progressing fatal neurologic disorder commonly caused by dominant variants in the <i>CSF1R</i> gene. The pathological hallmarks include demyelination of brain white matter, swollen axons, and pigmented glial cells. Clinically, ALSP is characterized by a constellation of symptoms including personality changes, cognitive dysfunction and motor impairments. There are no FDA approved treatments for ALSP. Limited natural history data is available to inform development of therapeutics for ALSP. <h3>Design/Methods:</h3> This is a prospective, multicenter, natural history study of patients with ALSP and asymptomatic carriers of <i>CSF1R</i> gene mutations. Up to 36 participants will be enrolled and followed for 24 months. Clinical assessments (cognitive, motor, functional, psychiatric, severity of illness, and caregiver burden) and MRI will be collected at Screening and at months 6, 12, 18, and 24. MRI severity score (Sundal et al 2012), white matter lesion and regional brain volumes will be derived. Blood and CSF (in a subset of participants) biomarkers of disease will be measured at specific visits. <h3>Results:</h3> 28 participants with confirmed <i>CSF1R</i> gene mutation meeting study eligibility criteria have been enrolled as of 9/2/2022. Among these, 17 were symptomatic and 11 were asymptomatic carriers, 13 were women and mean age at Screening visit was 46±13 years. Study enrollment is ongoing. Detailed study design and baseline characteristics of enrolled participants will be presented. <h3>Conclusions:</h3> This is the first systematic prospective study characterizing the natural history of ALSP due to <i>CSF1R</i> gene mutations leveraging standardized clinical, imaging and biomarker measurements. The outcome of this study is expected to inform on optimal biomarker and clinical endpoints and design of therapeutic intervention studies in ALSP. <b>Disclosure:</b> Dr. Rajagovindan has received personal compensation for serving as an employee of Biogen. Dr. Rajagovindan has received personal compensation for serving as an employee of Vigil. Dr. Rajagovindan has stock in Biogen. Dr. Rajagovindan has stock in Vigil . Mr. Matys has received personal compensation for serving as an employee of Vigil Neuroscience. Dr. Finger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vigil Neuro. Dr. Finger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali Therapeutics. The institution of Dr. Finger has received research support from CIHR. The institution of Dr. Finger has received research support from Physician Servcices Incorporated. The institution of Dr. Finger has received research support from Weston Foundation. Dr. Finger has received personal compensation in the range of $500-$4,999 for serving as a Annual Meeting Course Director with American Academy of Neurology. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant and Expert, Vaccine Injury Compensation Program with United States Health and Human Services and Department of Justice. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities. Wolfgang Koehler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Minoryx. Wolfgang Koehler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vigil. Wolfgang Koehler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for United Leukodystrophy Foundation. Wolfgang Koehler has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for European Leukodystrophy Association. The institution of Wolfgang Koehler has received research support from Minoryx. The institution of Wolfgang Koehler has received research support from Vigil. The institution of Wolfgang Koehler has received research support from SwanBio. The institution of Wolfgang Koehler has received research support from Alexion. The institution of Dr. Kumar has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Supernus. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. The institution of Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Teva Pharmaceuticals. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Annexon. The institution of Dr. Kumar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda Therapeutics. The institution of Dr. Kumar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cerevel Therapeutics. Dr. Kumar has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Impel Pharma. Dr. Kumar has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Supernus. The institution of Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda Therapeutics. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Kumar has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Research Catalyst, LLC. Dr. Kumar has stock in Research Catalyst, LLC. Dr. Kumar has stock in CenExel. The institution of Dr. Kumar has received research support from Supernus. The institution of Dr. Kumar has received research support from Sage Therapeutics. The institution of Dr. Kumar has received research support from Prilenia Therapeutics. The institution of Dr. Kumar has received research support from Roche. The institution of Dr. Kumar has received research support from Triplet Therapeutics. The institution of Dr. Kumar has received research support from CHDI Foundation. The institution of Dr. Kumar has received research support from Neurocrine Biosciences. The institution of Dr. Kumar has received research support from Biovie. The institution of Dr. Kumar has received research support from Neuroderm. The institution of Dr. Kumar has received research support from Sanofi. The institution of Dr. Kumar has received research support from Addex Pharma. The institution of Dr. Kumar has received research support from Integrative Research Laboratories. The institution of Dr. Kumar has received research support from Takeda Pharmaceuticals. The institution of Dr. Kumar has received research support from Neuraly. The institution of Dr. Kumar has received research support from Abbvie. The institution of Dr. Kumar has received research support from Cerevel Therapeutics. The institution of Dr. Kumar has received research support from Transposon Therapeutics. The institution of Dr. Kumar has received research support from Lundbeck. The institution of Dr. Kumar has received research support from Biohaven. The institution of Dr. Kumar has received research support from Revance Therapeutics. The institution of Dr. Kumar has received research support from Impax Laboratories. The institution of Dr. Kumar has received research support from Pharma Two B. The institution of Dr. Kumar has received research support from Enterin. The institution of Dr. Kumar has received research support from CND Life Sciences. The institution of Dr. Kumar has received research support from Neuron23. The institution of Dr. Kumar has received research support from Annexon Biosciences. The institution of Dr. Kumar has received research support from Annovis. The institution of Dr. Kumar has received research support from PTC Therapeutics. The institution of Dr. Kumar has received research support from Uniqure. The institution of Dr. Kumar has received research support from Alexza. The institution of Dr. Kumar has received research support from SparkNeuro. The institution of Dr. Kumar has received research support from Praxis. The institution of Dr. Kumar has received research support from Scion Neurostim. The institution of Dr. Kumar has received research support from Cognition Therapeutics. The institution of Dr. Kumar has received research support from Eli Lilly. Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as a Medical Director with CenExel RMCR. Dr. Kumar has received personal compensation in the range of $1,000,000+ for serving as a Managing Member with Research Catalyst, LLC. Dr. Lynch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Vigil Neuroscience. Dr. Orthmann Murphy has received research support from Conrad N. Hilton Foundation. Dr. Orthmann Murphy has received research support from Institute for Translational Medicine and Therapeutics’ (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics, University of Pennsylvania. The institution of Dr. Orthmann Murphy has received research support from Vigil Neurosciences. The institution of Dr. Orthmann Murphy has received research support from National MS Society. Dr. Orthmann Murphy has received personal compensation in the range of $500-$4,999 for serving as a Invited Speaker with Temple University . Dr. Orthmann Murphy has received personal compensation in the range of $0-$499 for serving as a Consultant with American Neurological Association. Dr. Schols has received personal compensation in the range of $500-$4,999 for serving as a Consultant for VICO Therapeutics. Dr. Schols has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Schols has received research support from Vigil. The institution of Nicole Wolf has received research support from ZonMW. Andreas Meier has received personal compensation for serving as an employee of Voyager Therapeutics. Andreas Meier has received personal compensation for serving as an employee of Biogen. Dr. Papapetropoulos has received personal compensation for serving as an employee of Vigil Neuroscience . Dr. Papapetropoulos has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Acadia. Dr. Papapetropoulos has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ventus Therapeutics Inc. Dr. Papapetropoulos has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Adamas Pharmaceuticals. Dr. Papapetropoulos has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Lipocine Inc. Dr. Papapetropoulos has stock in Vigil Neuroscience. Dr. Papapetropoulos has stock in Adamas. Dr. Papapetropoulos has stock in Lipocine. Dr. Wszolek has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Polish Neurological Society/Via Medica." @default.
• W4367305046 created "2023-04-29" @default.
• W4367305046 creator A5023897162 @default.
• W4367305046 creator A5024969724 @default.
• W4367305046 creator A5032527086 @default.
• W4367305046 creator A5040364341 @default.
• W4367305046 creator A5056257024 @default.
• W4367305046 creator A5060664922 @default.
• W4367305046 creator A5061426453 @default.
• W4367305046 creator A5067483880 @default.
• W4367305046 creator A5067571783 @default.
• W4367305046 creator A5068759656 @default.
• W4367305046 creator A5072242679 @default.
• W4367305046 creator A5081810765 @default.
• W4367305046 creator A5085126904 @default.
• W4367305046 creator A5085825554 @default.
• W4367305046 date "2023-04-25" @default.
• W4367305046 modified "2023-09-27" @default.
• W4367305046 title "A Prospective Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (S49.008)" @default.
• W4367305046 doi "https://doi.org/10.1212/wnl.0000000000203073" @default.
• W4367305046 hasPublicationYear "2023" @default.
• W4367305046 type Work @default.
• W4367305046 citedByCount "0" @default.
• W4367305046 crossrefType "proceedings-article" @default.
• W4367305046 hasAuthorship W4367305046A5023897162 @default.
• W4367305046 hasAuthorship W4367305046A5024969724 @default.
• W4367305046 hasAuthorship W4367305046A5032527086 @default.
• W4367305046 hasAuthorship W4367305046A5040364341 @default.
• W4367305046 hasAuthorship W4367305046A5056257024 @default.
• W4367305046 hasAuthorship W4367305046A5060664922 @default.
• W4367305046 hasAuthorship W4367305046A5061426453 @default.
• W4367305046 hasAuthorship W4367305046A5067483880 @default.
• W4367305046 hasAuthorship W4367305046A5067571783 @default.
• W4367305046 hasAuthorship W4367305046A5068759656 @default.
• W4367305046 hasAuthorship W4367305046A5072242679 @default.
• W4367305046 hasAuthorship W4367305046A5081810765 @default.
• W4367305046 hasAuthorship W4367305046A5085126904 @default.
• W4367305046 hasAuthorship W4367305046A5085825554 @default.
• W4367305046 hasConcept C126322002 @default.
• W4367305046 hasConcept C163276114 @default.
• W4367305046 hasConcept C169760540 @default.
• W4367305046 hasConcept C175369904 @default.
• W4367305046 hasConcept C2778279407 @default.
• W4367305046 hasConcept C54355233 @default.
• W4367305046 hasConcept C71924100 @default.
• W4367305046 hasConcept C81885089 @default.
• W4367305046 hasConcept C86803240 @default.
• W4367305046 hasConceptScore W4367305046C126322002 @default.
• W4367305046 hasConceptScore W4367305046C163276114 @default.
• W4367305046 hasConceptScore W4367305046C169760540 @default.
• W4367305046 hasConceptScore W4367305046C175369904 @default.
• W4367305046 hasConceptScore W4367305046C2778279407 @default.
• W4367305046 hasConceptScore W4367305046C54355233 @default.
• W4367305046 hasConceptScore W4367305046C71924100 @default.
• W4367305046 hasConceptScore W4367305046C81885089 @default.
• W4367305046 hasConceptScore W4367305046C86803240 @default.
• W4367305046 hasLocation W43673050461 @default.
• W4367305046 hasOpenAccess W4367305046 @default.
• W4367305046 hasPrimaryLocation W43673050461 @default.
• W4367305046 hasRelatedWork W1969800110 @default.
• W4367305046 hasRelatedWork W1991380795 @default.
• W4367305046 hasRelatedWork W1994215616 @default.
• W4367305046 hasRelatedWork W2037532264 @default.
• W4367305046 hasRelatedWork W2042833942 @default.
• W4367305046 hasRelatedWork W2057721052 @default.
• W4367305046 hasRelatedWork W3195278863 @default.
• W4367305046 hasRelatedWork W4235137802 @default.
• W4367305046 hasRelatedWork W4286110639 @default.
• W4367305046 hasRelatedWork W4322706569 @default.
• W4367305046 isParatext "false" @default.
• W4367305046 isRetracted "false" @default.
• W4367305046 workType "article" @default.